“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 09/06/2023
USD1.94
▲ −0.02 (−1.02%)
Market capitalisation
USD123m
Incannex Healthcare is an Australian dual-listed biotech company focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. These therapies are being designed to target indications with unmet need, including obstructive sleep apnea, generalized anxiety disorder, trauma and inflammatory conditions.
Management’s strategy to pursue synergistic combination patent filings of its assets has the potential to create extensive protection within the cannabinoid treatment market. The IP position for the combinations will be further supported by method of use and formulation patents. Combination patents could therefore be a significant source of value for the company should approval be granted.
Managing Director - Head of Content, Healthcare
Joel Latham
CEO
Troy Valentine
Chairman
Forecast net cash (A$m)
29.6
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 0.4 | (23.6) | (71.0) |
| Relative | (3.2) | (29.0) | (72.2) |
| 52 week high/low | US$6.5/US$1.8 |
Incannex Healthcare specializes in the development of treatments for chronic conditions using cannabinoids and psychedelics, leveraging its synergistic combination IP. Recently, it achieved proof-of-concept in Australia for IHL-42X, its lead asset for the treatment of obstructive sleep apnea. Incannex intends to file an investigational new drug application with the FDA in CY23. Interim safety data reported in Q123 from the ongoing (Australian) Phase II trial of psilocybin in combination with psychotherapy in generalized anxiety disorder were positive and an independent safety review recommended no changes to the study design; final data are expected in Q423. Final results for ILH-675A in the Phase I trial were announced in Q223; the asset is now being assessed in Phase II for the treatment of rheumatoid arthritis.
| Y/E Jun | Revenue (A$m) | EBITDA (A$m) | PBT (A$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 2.0 | N/A | (8.2) | (0.83) | N/A | N/A |
| 2022A | 0.8 | N/A | (14.9) | (1.25) | N/A | N/A |
| 2023E | 0.1 | N/A | (20.7) | (1.43) | N/A | N/A |
| 2024E | 0.1 | N/A | (33.4) | (2.10) | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
